The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
about
β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literatureThe Genetic Challenges and Opportunities in Advanced Heart FailureRace, sex, and age differences in heart failure-related hospitalizations in a southern state: implications for prevention.Can intellectualism stifle scientific discovery?Expanding role of beta-blockade in the management of chronic heart failure.THE ROLE OF β-ADRENERGIC RECEPTORS IN HEART FAILURE: DIFFERENTIAL REGULATION OF CARDIOTOXICITY AND CARDIOPROTECTION.Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database.Inverse agonism: more than reverting constitutively active receptor signaling.Management of chronic heart failure: an old disease with a new face.Chronic Heart Failure Clinical Practice Guidelines' Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy?Effect of race on left ventricular ejection fraction decline after initial improvement with beta blockers in patients with non-ischemic cardiomyopathy: a retrospective analysis.Sudden cardiac death: history, aetiology and management.Privileged frameworks from snake venom.Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy.The relevance of comorbidities for heart failure treatment in primary care: A European survey.Clinical and echocardiographic outcome in patients receiving carvedilol for treatment of dilated cardiomyopathy.Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes.Effects of β-adrenergic blockade on left ventricular remodeling among Hispanics and African Americans with chronic heart failure.
P2860
Q26861630-036807D5-20C7-465A-9278-F430038B0FB0Q33653498-F92AFF60-9C45-44D5-851F-EC8C656852B3Q34760994-0F059C37-9E00-4313-9FE4-16651542C7C4Q34932240-940AB5BE-716A-4E8F-B517-0D0D88230174Q35101463-52C53632-3318-42D9-8207-0818B7339E44Q35104064-8988070A-19EB-4FE6-B90D-985B55276C8AQ35819739-27F65DC4-50A1-48E3-B73D-FA10CDAA89A2Q36021535-B04459BA-E495-4ADE-8D67-70FB9824D47FQ36083086-A1311208-84F5-43BD-8ED9-BF388D9731D2Q36661094-FF357DC2-3F77-4D62-9175-850EE2BBD1F1Q37199806-9B97DEDA-9B3C-4F0E-A0D0-C0ACA6B82E00Q37396776-3EA7CEC9-B347-423E-9FB1-661907BBA17DQ38360688-78325298-BE19-4137-8E8A-3702CEE8577FQ43225799-73C9848F-6E24-4DFA-A357-12F69DEB6430Q43944121-3ECB5ED9-C2F9-4058-B648-27A33CF0250DQ46347497-90492ED6-8809-4C44-A420-69CBB1F6C428Q46616130-78CDF005-5FAA-40F2-9D26-CBC4716C3421Q46710424-9C0F59F8-E086-459D-B367-EE81AA4AE055
P2860
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
description
2001 nî lūn-bûn
@nan
2001 թուականին հրատարակուած գիտական յօդուած
@hyw
2001 թվականին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
@ast
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
@en
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
@nl
type
label
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
@ast
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
@en
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
@nl
prefLabel
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
@ast
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
@en
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
@nl
P2860
P356
P1476
The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
@en
P2093
Eric J Eichhorn
Michael R Bristow
P2860
P2888
P356
10.1186/CVM-2-1-020
P577
2001-01-01T00:00:00Z
P5875
P6179
1049042116